About
Okomera develops a platform that uses microfluidic tumor-on-chip technology combined with AI imaging to rapidly test personalized drug responses from patient-derived cancer biopsies, enabling improved cancer treatment decisions and drug development.
Explore Okomera's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.